Antibe Therapeutics Inc. | Income Statement
Fiscal year is April-March. All values CAD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
-
4,431.20
9,054.40
8,510.10
Cost of Goods Sold (COGS) incl. D&A
-
-
2,538.90
5,473.20
5,512.00
Gross Income
-
-
1,892.30
3,581.20
2,998.10
SG&A Expense
2,776.10
4,504.50
5,040.90
8,789.90
9,662.20
EBIT
2,776.10
4,504.50
-
5,208.70
6,664.10
Non Operating Income/Expense
-
-
6.30
70.60
120.20
Interest Expense
15.20
-
347.40
835.20
1,178.00
Pretax Income
2,784.90
4,484.60
3,496.30
6,110.80
7,704.60
Income Tax
104.90
83.40
131.60
365.00
274.80
Consolidated Net Income
2,680.10
4,401.20
3,364.70
5,745.80
7,429.80
Net Income
2,680.10
4,401.20
3,364.70
5,745.80
7,429.80
Net Income After Extraordinaries
2,680.10
4,401.20
3,364.70
5,745.80
7,429.80
Net Income Available to Common
2,680.10
4,401.20
3,364.70
5,745.80
7,429.80
EPS (Basic)
0.10
0.12
0.05
0.06
0.05
Basic Shares Outstanding
26,173.50
36,934.00
62,746.80
95,744.80
151,621.90
EPS (Diluted)
0.10
0.12
0.05
0.06
0.05
Diluted Shares Outstanding
26,173.50
36,934.00
62,746.80
95,744.80
151,621.90
EBITDA
2,776.10
4,504.50
2,989.90
4,856.10
6,287.00
Non-Operating Interest Income
6.30
20.00
5.90
3.60
17.30
About Antibe Therapeutics
View Profile
